Topoisomerase inhibitors - Study guides, Class notes & Summaries

BMTCN Review Chapter 7 - Survivorship IssuesSurvivors and Survivorship - correct answer An individual is considered a cancer survivor from the time of diagnosis through the balance of his/her life Survivorship is a distinct phase of the cancer experience Some patients do not embrace the term "cancer survivor" Some definitions acknowledge the impact of cancer survivorship on families, friends and caregivers HSCT Survivorship - correct answer Number is increasing -Improvements in ou...

BMTCN-- Question and answers already passed 2023/2024 What type of transplants commonly have PTLD as a secondary malignancy? - correct answer Allo HSCT with T-cell depleted graft Therapies associated with therapy-related acute leukemia and MDS - correct answer alkylating agents (eg. Cytoxan, cisplatin, melphalan, busulfan, ifos) , radiation, topoisomerase II inhibitors (eg. doxorubicin, etoposide, mitoxantrone) Genetic predispositions that increase risk of primary and secondary cancers - ...

BMTCN2 Question and answers correctly solved 2023/2024 What type of transplants commonly have PTLD as a secondary malignancy? - correct answer Allo HSCT with T-cell depleted graft Therapies associated with therapy-related acute leukemia and MDS - correct answer alkylating agents (eg. Cytoxan, cisplatin, melphalan, busulfan, ifos) , radiation, topoisomerase II inhibitors (eg. doxorubicin, etoposide, mitoxantrone) Genetic predispositions that increase risk of primary and secondary cancers -...

What type of transplants commonly have PTLD as a secondary malignancy? - ANSWER-Allo HSCT with T-cell depleted graft Therapies associated with therapy-related acute leukemia and MDS - ANSWER-alkylating agents (eg. Cytoxan, cisplatin, melphalan, busulfan, ifos) , radiation, topoisomerase II inhibitors (eg. doxorubicin, etoposide, mitoxantrone) Genetic predispositions that increase risk of primary and secondary cancers - ANSWER-neurofibromatosis type 1, Fanconi anemia Risk factors for PTLD ...

What type of transplants commonly have PTLD as a secondary malignancy? - ️️Allo HSCT with T-cell depleted graft Therapies associated with therapy-related acute leukemia and MDS - ️️alkylating agents (eg. Cytoxan, cisplatin, melphalan, busulfan, ifos) , radiation, topoisomerase II inhibitors (eg. doxorubicin, etoposide, mitoxantrone) Genetic predispositions that increase risk of primary and secondary cancers - ️️neurofibromatosis type 1, Fanconi anemia Risk factors for PTLD -...

USLME Biochem - First Aid Exam Questions With Accurate Answers. Chromatin structure - answerDNA exists in condensed chromatin form in order to fit in nucleus Negatively charged DNA loops twice around positively charged histone octamer (2 sets of H2A, H2B, H3 and H4) to form nucleosome "bead" Octomer subunits consist primarily of lysine and arginine amino acids (positively charged). H1 ties nucleosome beads together in a string Heterochromatin - answerCondensed, transciptionally inactiv...

What type of transplants commonly have PTLD as a secondary malignancy? - ANSWER-Allo HSCT with T-cell depleted graft Therapies associated with therapy-related acute leukemia and MDS - ANSWER-alkylating agents (eg. Cytoxan, cisplatin, melphalan, busulfan, ifos) , radiation, topoisomerase II inhibitors (eg. doxorubicin, etoposide, mitoxantrone) Genetic predispositions that increase risk of primary and secondary cancers - ANSWER-neurofibromatosis type 1, Fanconi anemia Risk factors for PTLD ...

BMTCN Review Chapter 4 - Transplant Preparative Regimens, Cellular Infusion, Acute Complications, and EngraftmentTRANSPLANT PREP REGIMENS - correct answer Treatment leading up to transplant Acronyms: Ara-C BCNU BU Cy DLT SCT TBI - correct answer Cytarabine Carmustine Busulfan Cyclophosphamide Dose limiting toxicity DStem cell transplant Total body irradiation Induction chemotherapy - correct answer The first treatment given for a disease. It is often part of a standard set of ...

Predictors of PDL1/PD1 inhibitor response Presence of tumor CD8 cell infiltration High cancer genome burden High levels of cancer PD-L1 expression (PD1 is on the cytotoxic T cell) Ipilimumab CTLA4 inhibitor Nivolumab PD-1 inhibitor Regorafenib VEGF inhibitor Bevacizumab Monoclonal antibody against VEGF-A. Inhibits angiogenesis. Pembrolizumab PD-1 inhibitor Atezolizumab PD-L1 inhibitor Avelumab PD-L1 inhibitor Durvalumab PD-L1 inhibitor Cemiplimab PD-1 inhibitor fo...

What type of transplants commonly have PTLD as a secondary malignancy? - ANSWER-Allo HSCT with T-cell depleted graft Therapies associated with therapy-related acute leukemia and MDS - ANSWER-alkylating agents (eg. Cytoxan, cisplatin, melphalan, busulfan, ifos) , radiation, topoisomerase II inhibitors (eg. doxorubicin, etoposide, mitoxantrone) Genetic predispositions that increase risk of primary and secondary cancers - ANSWER-neurofibromatosis type 1, Fanconi anemia Risk factors for PTLD ...